Sensex 29448.95 68.22 0.23%
Nifty 8937.75 15.1 0.17%
Ex - US & Ex - UK Medical Media Only
Boehringer Ingelheim and Eli Lilly and Company today announced they will feature five oral and 12 poster presentations for linagliptin and the investigational compound empagliflozin* at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD) which will take place in Barcelona, from 23 – 27 September. The presentations will add to the already existing body of data on safety and efficacy of these two compounds.
A total of eight clinical and pre-clinical abstracts for the investigational agent empagliflozin will be presented. Empagliflozin is a member of the sodium glucose cotransporter 2 (SGLT2) inhibitor class of drugs and is being investigated for the reduction of blood glucose levels in adults with Type 2 Diabetes (T2D).
Details of clinical empagliflozin presentations and published abstracts are as follows:1
Tuesday, 24 September, 12:30–13:30 CET, General Poster Session
Tuesday, 24 September, 13:45–14:45 CET, General Poster Session
Wednesday, 25 September, 12:30–13:30 CET, General Poster Session
Thursday, 26 September, 15:00 – 16:30 CET, Oral Presentation
* Empagliflozin is an investigational compound. Its safety and efficacy have not been established.
A total of nine clinical and pre-clinical abstracts for linagliptin will also be presented. Linagliptin is an inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4), which breaks down the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) that are involved with regulating blood glucose.2
Details of all clinical presentations and published abstracts are as follows:1
Wednesday, 25 September, 10:45 – 12:15 CET, Oral Presentation
Wednesday, 25 September, 12:30 – 13:30 CET, General Poster Session
Wednesday, 25 September, 15:00 – 16:30 CET, Oral Presentation
Thursday, 26 September, 10:45 – 12:15 CET, Oral Presentation
Thursday, 26 September, 12:30 – 13:30 CET, General Poster Session
Thursday, 26 September, 13:45 – 14:45 CET, General Poster Session
Linagliptin, which is marketed as Trajenta® 5mg tablets in Europe, is a once-daily tablet used along with diet and exercise to improve glycaemic control in adults with Type 2 Diabetes. Linagliptin should not be used in patients with Type 1 Diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine). Linagliptin is the only approved DPP-4 inhibitor that does not require dose adjustments regardless of renal or hepatic function.
Please click on the link below for ‘Notes to Editors’ and ‘References’:
India Infoline News Service / 08:51, Feb 27, 2015
The outlook is a positive start .The unwinding of positions and rollover in the F&O expiry brought in the usual volatility on Thursday.